Marrone Bio Innovations, Inc.

NasdaqCM:MBII Stock Report

Market Cap: US$145.6m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Marrone Bio Innovations Management

Management criteria checks 4/4

Key information

Kevin Helash

Chief executive officer

US$416.6k

Total compensation

CEO salary percentage96.98%
CEO tenure1.9yrs
CEO ownership0.05%
Management average tenure4.5yrs
Board average tenure4.2yrs

Recent management updates

No updates

Recent updates

Seeking Alpha • Jul 11

Marrone Bio Innovations shareholders approve merger deal with Bioceres Crop Solutions

Marrone Bio Innovations (NASDAQ:MBII) on Monday said its shareholders had approved the proposed merger agreement with Bioceres Crop Solutions (BIOX). BIOX and MBII announced the proposed deal in March, as per which BIOX would acquire MBII in an all-stock transaction. The companies had said that each MBII share will be exchanged at closing for BIOX shares at a fixed ratio of 0.088, representing a value of ~$236M. MBII on Monday said its shareholders met at a special shareholder meeting on July 8 and approved the proposal. MBII said the companies intend to close the deal on July 12. MBII stock -2.4% at $1.03 in morning trading, while BIOX was down 1.5% at $12.04.
Analysis Article • Aug 21

Time To Worry? Analysts Are Downgrading Their Marrone Bio Innovations, Inc. (NASDAQ:MBII) Outlook

The latest analyst coverage could presage a bad day for Marrone Bio Innovations, Inc. ( NASDAQ:MBII ), with the...
Analysis Article • Apr 08

Marrone Bio Innovations, Inc. (NASDAQ:MBII) Is Expected To Breakeven In The Near Future

Marrone Bio Innovations, Inc. ( NASDAQ:MBII ) is possibly approaching a major achievement in its business, so we would...
Analysis Article • Mar 13

Is Marrone Bio Innovations (NASDAQ:MBII) Using Too Much Debt?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Analysis Article • Feb 15

What Kind Of Investors Own Most Of Marrone Bio Innovations, Inc. (NASDAQ:MBII)?

Every investor in Marrone Bio Innovations, Inc. ( NASDAQ:MBII ) should be aware of the most powerful shareholder...
Analysis Article • Jan 25

Marrone Bio Innovations (NASDAQ:MBII) Shareholders Have Enjoyed A 75% Share Price Gain

When you buy and hold a stock for the long term, you definitely want it to provide a positive return. But more than...
Analysis Article • Jan 04

When Will Marrone Bio Innovations, Inc. (NASDAQ:MBII) Turn A Profit?

We feel now is a pretty good time to analyse Marrone Bio Innovations, Inc.'s ( NASDAQ:MBII ) business as it appears the...
Analysis Article • Dec 09

Does Marrone Bio Innovations (NASDAQ:MBII) Have A Healthy Balance Sheet?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

CEO Compensation Analysis

How has Kevin Helash's remuneration changed compared to Marrone Bio Innovations's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2022n/an/a

-US$21m

Dec 31 2021US$417kUS$404k

-US$17m

Sep 30 2021n/an/a

-US$15m

Jun 30 2021n/an/a

-US$17m

Mar 31 2021n/an/a

-US$16m

Dec 31 2020US$1mUS$155k

-US$20m

Compensation vs Market: Kevin's total compensation ($USD416.64K) is below average for companies of similar size in the US market ($USD787.45K).

Compensation vs Earnings: Kevin's compensation has been consistent with company performance over the past year.

CEO

Kevin Helash (57 yo)

1.9yrs
Tenure
US$416,642
Compensation

Mr. Kevin R. Helash serves as Chief Executive Officer and Director at Marrone Bio Innovations, Inc. since August 03, 2020. He had been the Chief Executive Officer of Agrinos AS since November 20, 2017 unti...

Leadership Team

NamePositionTenureCompensationOwnership
Kevin Helash
CEO & Director1.9yrsUS$416.64k0.045%
$ 65.9k
Pamela Marrone
Founder16.5yrsUS$254.58k1.21%
$ 1.8m
Linda Moore
Chief Compliance Officer8.3yrsUS$316.74k0.013%
$ 18.9k
LaDon Johnson
Interim Chief Financial Officerless than a yearno datano data
Amit Vasavada
Senior VP of Research Development & Chief Technical Officer5.3yrsno data0.022%
$ 31.4k
Andre Trepanier
Director of Marketingno datano datano data
Barner Jones
Director of National Sales & Account Management3.8yrsno datano data
Matti Tiainen
Senior Vice President of International Sales1.4yrsno data0.0026%
$ 3.7k
Keith Pitts
Senior VP of Regulatory & Government Affairs and Chief Sustainability Officer5.9yrsno data0.0026%
$ 3.8k
4.5yrs
Average Tenure
61.5yo
Average Age

Experienced Management: MBII's management team is considered experienced (4.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Kevin Helash
CEO & Director1.9yrsUS$416.64k0.045%
$ 65.9k
Pamela Marrone
Founder16.5yrsUS$254.58k1.21%
$ 1.8m
Stuart Woolf
Independent Director3.9yrsUS$83.83k0%
$ 0
Robert Woods
Independent Chairman4.4yrsUS$112.02k0.0074%
$ 10.8k
William Fenical
International Science Advisory Panel Memberno datano datano data
Zachary Wochok
Independent Director6.2yrsUS$93.23k0.0032%
$ 4.6k
Roberta Farrell
International Science Advisory Panel Memberno datano datano data
Gabriele Berg
International Science Advisory Panel Memberno datano datano data
Trevor Jackson
International Science Advisory Panel Memberno datano datano data
Henk Noorman
International Science Advisory Panel Memberno datano datano data
Orlando Rojas
International Science Advisory Panel Memberno datano datano data
Keith McGovern
Independent Director3.9yrsUS$81.82k0%
$ 0
4.2yrs
Average Tenure
63.5yo
Average Age

Experienced Board: MBII's board of directors are considered experienced (4.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2022/07/13 23:17
End of Day Share Price 2022/07/12 00:00
Earnings2022/03/31
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Marrone Bio Innovations, Inc. is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Nathan WeinsteinAegis Capital Corporation
Benjamin KalloBaird
Robert BurlesonCanaccord Genuity